secwatch.observer — SEC 8-K summary
======================================

Issuer:     Schrodinger, Inc. (SDGR)
CIK:        0001490978
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001490978-25-000013
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Schrödinger Q4 software revenue $79.7M (+16% YoY); 2025 outlook: rev growth 10-15%, drug disc rev $45-50M
--------------------------------------------------------------------------------

- Q4 2024 total revenue $88.3M (+19% YoY); software revenue $79.7M (+16% YoY).
- Full-year 2024 net loss $187.1M vs net income $40.7M in 2023; non-GAAP net loss $191.4M.
- Cash, equivalents, and marketable securities $367.5M at Dec 31, 2024; received $150M upfront from Novartis in Jan 2025.
- 2025 guidance: software revenue growth 10-15%; drug discovery revenue $45-50M; software gross margin 74-75%; OpEx growth <5%.
- Expanded collaboration with Lilly (undisclosed target); Novartis collaboration cleared with $150M payment received.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1490978/000149097825000013/0001490978-25-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1490978/000149097825000013/sdgr-20250226.htm
  HTML page:      https://secwatch.observer/filing/0001490978-25-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer